How Much Does CJC-1295 (no DAC), Ipamorelin 10mg (Blend) Cost in 2026? Pricing Breakdown

How Much Does CJC-1295 (no DAC), Ipamorelin 10mg (Blend) Cost in 2026? Complete Pricing Breakdown

Key Takeaways

• CJC-1295 (no DAC), Ipamorelin 10mg (Blend) costs $200-$800 monthly through research peptide programs, with consultation fees adding $150-$500 initially
• This peptide blend is research-only and not FDA-approved, limiting availability to specialized research clinics and academic programs^[1]
• Insurance does not cover research-only peptides, making all costs out-of-pocket expenses
• HSA/FSA funds cannot be used for research peptides without FDA-approved medical indications
• Monthly program costs vary significantly based on dosing protocols, with 100mcg CJC-1295 + 100mcg Ipamorelin daily costing $300-$600 monthly
• Research participation through clinical trials may provide free access to this peptide combination under IRB-approved protocols

What Is CJC-1295 (no DAC), Ipamorelin 10mg (Blend)?

CJC-1295 (no DAC), Ipamorelin 10mg (Blend) is a research peptide combination that pairs two growth hormone secretagogues with distinct mechanisms of action. CJC-1295 without DAC (Drug Affinity Complex) stimulates growth hormone synthesis through GHRH receptors with a 30-minute half-life, while Ipamorelin activates calcium signaling via the ghrelin receptor with minimal cortisol or prolactin elevation.^[2] This blend carries research-only status from the FDA, significantly affecting pricing and availability compared to FDA-approved peptide therapies.

CJC-1295 (no DAC), Ipamorelin 10mg (Blend) Cost Overview

Detailed Cost Breakdown

Research Peptide Supply Cost

CJC-1295 (no DAC), Ipamorelin 10mg (Blend) vials typically contain 10mg total peptide content, with ratios varying from 5mg/5mg to 3mg/7mg depending on the research protocol.^[3] Monthly supply costs range from $200-$800 based on dosing frequency and vial concentration. Research-grade peptides command premium pricing due to specialized synthesis requirements and limited production volumes compared to FDA-approved medications.

Standard research dosing protocols utilize 100-300mcg of each peptide daily, administered subcutaneously 30 minutes before meals or bedtime.^[4] A 10mg blend vial provides approximately 16-50 doses depending on individual peptide concentrations and prescribed amounts. Research clinics typically charge $12-$16 per dose when factoring in peptide cost, reconstitution supplies, and handling fees.

Consultation and Program Fees

Initial consultations for research peptide programs cost $150-$500, with specialized hormone optimization clinics charging premium rates for comprehensive evaluations.^[5] These consultations include medical history review, physical examination, discussion of research protocols, and informed consent documentation required for research peptide participation.

Monthly follow-up appointments range from $75-$200, with telehealth options typically 30-40% less expensive than in-person visits. Research programs require more frequent monitoring than FDA-approved therapies, with monthly check-ins standard during the first 3 months of participation. Some clinics offer all-inclusive monthly programs at $450-$900 that bundle consultation, peptide supply, and basic monitoring services.

Required Laboratory Work

Baseline laboratory testing costs $250-$600 and includes IGF-1 levels ($85-$120), comprehensive metabolic panel ($45-$75), lipid panel ($35-$55), and complete blood count ($25-$40).^[6] Research protocols often require additional markers like growth hormone stimulation tests ($200-$350) or 24-hour urine growth hormone measurements ($150-$250).

Monitoring labs every 8-12 weeks cost $150-$300, focusing primarily on IGF-1 levels and metabolic markers. Research participants may require more frequent testing than clinical patients, with some protocols mandating monthly IGF-1 measurements during dose optimization phases. Laboratory costs represent 15-25% of total program expenses over the first year.

Insurance Coverage Deep Dive

Insurance plans do not cover research-only peptides like CJC-1295 (no DAC), Ipamorelin 10mg (Blend) since they lack FDA approval for any medical indication.^[7] Major insurers including Aetna, Blue Cross Blue Shield, Cigna, and UnitedHealthcare explicitly exclude experimental or investigational treatments from coverage unless part of approved clinical trials.

Medicare and Medicaid similarly exclude research peptides from coverage, with Medicare Part B specifically requiring FDA approval for injectable medications. Private insurance appeals for research peptide coverage have success rates below 5%, even with physician letters of medical necessity.^[8] Patients should expect 100% out-of-pocket costs for all aspects of research peptide therapy.

Some insurance plans may cover required laboratory testing if ordered for general health monitoring rather than specifically for peptide therapy monitoring. Providers can sometimes bill IGF-1 testing under diagnostic codes for growth hormone deficiency evaluation (E23.0) rather than experimental treatment monitoring.

HSA/FSA Eligibility

Health Savings Account (HSA) and Flexible Spending Account (FSA) funds cannot be used for research-only peptides without FDA-approved medical indications.^[9] IRS Publication 502 specifically excludes experimental treatments unless they are part of approved clinical trials or have received FDA authorization for the patient's specific condition.

Laboratory testing may qualify for HSA/FSA reimbursement if ordered for diagnostic purposes rather than research monitoring. Consultation fees with licensed physicians generally qualify for HSA/FSA payment regardless of the treatment discussed. Patients should maintain detailed records and consult tax professionals before using HSA/FSA funds for any research peptide-related expenses.

Telehealth vs. In-Person Pricing

Telehealth research peptide programs cost $300-$600 monthly for comprehensive services including peptide supply, consultation, and basic monitoring.^[10] Popular telehealth platforms specializing in research peptides include specialized hormone clinics that operate in multiple states with licensed physicians overseeing protocols remotely.

In-person research clinics typically charge $500-$900 monthly for similar services, with the premium reflecting overhead costs for physical facilities and in-person examinations. However, in-person programs may offer more comprehensive monitoring including body composition analysis ($50-$100 per session) and detailed physical assessments not available through telehealth platforms.

Telehealth peptide clinics often provide better pricing transparency and standardized protocols compared to individual physician practices. Many telehealth programs include injection training videos, 24/7 support access, and automated peptide refill systems that reduce overall program complexity and hidden costs.

Ways to Reduce CJC-1295 (no DAC), Ipamorelin 10mg (Blend) Cost

Research peptide costs can be reduced through several strategies, though options remain limited compared to FDA-approved medications. Clinical trial participation offers the most significant cost reduction, with some research studies providing free peptide access, monitoring, and laboratory testing in exchange for participation in IRB-approved protocols.^[11]

Group purchasing through research organizations or peptide user communities can reduce per-vial costs by 10-20% through bulk ordering arrangements. Some research clinics offer payment plans or sliding fee scales based on income, particularly for patients participating in long-term research protocols requiring 6-12 month commitments.

Dose optimization represents another cost-reduction strategy, with some patients achieving desired research outcomes on lower doses after initial response assessment. Starting protocols at 100mcg daily and titrating based on IGF-1 response can reduce monthly peptide consumption by 25-40% compared to fixed high-dose regimens.

Cost Compared to Alternatives

Research peptide combinations like CJC-1295 (no DAC), Ipamorelin 10mg (Blend) occupy a middle ground between single-peptide protocols and direct growth hormone replacement therapy in terms of both cost and complexity.^[12] The blend typically costs 40-60% more than individual peptide protocols but provides synergistic effects that may justify the premium for research participants seeking comprehensive growth hormone axis stimulation.

What to Ask Your Provider About Cost

When evaluating CJC-1295 (no DAC), Ipamorelin 10mg (Blend) research programs, patients should ask specific cost-related questions to avoid unexpected expenses. "What is the total monthly cost including peptides, consultations, and required lab work?" helps establish comprehensive budget expectations rather than focusing solely on peptide pricing.

"Do you offer payment plans or sliding fee scales for research participants?" addresses affordability concerns upfront, as many research clinics have flexibility in payment arrangements not available through traditional medical practices. "How often are follow-up visits required, and what do they cost?" clarifies ongoing monitoring expenses beyond initial consultation fees.

"What happens to my cost if the research protocol changes or if I need to discontinue?" protects patients from unexpected financial obligations during protocol modifications. "Are there any additional fees for injection training, supplies, or emergency consultations?" reveals potential hidden costs that can significantly impact total program expenses.

"Do you provide detailed invoices that separate peptide costs from consultation fees for tax purposes?" helps patients who may be able to claim consultation fees through HSA/FSA accounts even if peptide costs are excluded.

FAQ

How much does CJC-1295 (no DAC), Ipamorelin 10mg (Blend) cost per month?

Monthly costs range from $350-$1,050 including peptide supply ($200-$800), monitoring visits ($75-$200), and injection supplies ($25-$50). Research-only status prevents insurance coverage, making all expenses out-of-pocket. Initial month costs are higher due to consultation fees ($150-$500) and baseline laboratory work ($250-$600).

Does insurance cover CJC-1295 (no DAC), Ipamorelin 10mg (Blend)?

No insurance plans cover research-only peptides without FDA approval. Major insurers including Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, Medicare, and Medicaid specifically exclude experimental treatments.^[13] Appeals have success rates below 5% even with physician support letters.

Is compounded CJC-1295 (no DAC), Ipamorelin 10mg (Blend) available?

Compounded versions are not legally available through traditional compounding pharmacies since the FDA has not approved these peptides for any medical indication. Only specialized research clinics and academic institutions can provide access through IRB-approved research protocols with proper informed consent documentation.

Can I use my HSA/FSA for this peptide blend?

HSA/FSA funds cannot be used for research-only peptides without FDA-approved indications according to IRS Publication 502.^[14] However, consultation fees with licensed physicians and some laboratory testing may qualify for reimbursement if billed for diagnostic rather than research monitoring purposes.

What's the cheapest way to get CJC-1295 (no DAC), Ipamorelin 10mg (Blend)?

Clinical trial participation offers the lowest cost option, potentially providing free peptide access and monitoring. Otherwise, telehealth research programs ($300-$600 monthly) typically cost less than in-person clinics ($500-$900 monthly). Group purchasing arrangements may reduce costs by 10-20% through bulk ordering.

Are telehealth programs cheaper than in-person clinics?

Yes, telehealth research programs typically cost 30-40% less than in-person clinics. Monthly telehealth programs range from $300-$600 compared to $500-$900 for in-person services. However, telehealth programs may have limitations in comprehensive physical monitoring and hands-on injection training.

Why is CJC-1295 (no DAC), Ipamorelin 10mg (Blend) so expensive?

Research-only status limits production to specialized facilities with higher manufacturing costs per unit. Small batch sizes, extensive quality testing requirements, and limited competition contribute to premium pricing compared to FDA-approved medications with large-scale manufacturing.^[15]

Does the cost go down over time?

Costs may decrease after the initial 3-month monitoring period when follow-up visits can be spaced further apart. Some patients achieve desired outcomes on lower maintenance doses, reducing monthly peptide consumption by 25-40%. However, research protocols typically require consistent monitoring throughout participation.

How do costs compare to growth hormone therapy?

CJC-1295 (no DAC), Ipamorelin 10mg (Blend) costs $350-$1,050 monthly compared to $800-$3,000 for growth hormone replacement therapy. However, growth hormone therapy may be partially covered by insurance for approved indications, while research peptides are entirely out-of-pocket expenses.

What additional costs should I budget for?

Beyond monthly program costs, budget for potential dose adjustments ($50-$100 per consultation), travel expenses for in-person visits, storage supplies for peptide refrigeration, and emergency consultation fees ($100-$200). Some programs charge additional fees for detailed progress reports or body composition monitoring.

References

1. FDA Center for Drug Evaluation and Research. "Guidance for Industry: Investigational New Drug Applications." FDA.gov. 2023. Accessed February 2026.
2. Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 16968804
3. Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone." J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
4. Beck DE, et al. "The role of ghrelin in the regulation of growth hormone secretion in normal and pathological conditions." Eur J Endocrinol. 2004;151(4):439-446. PMID: 15476442
5. American Association of Clinical Endocrinologists. "Clinical Practice Guidelines for Growth Hormone Use in Adults." Endocr Pract. 2019;25(12):1313-1328.
6. Clemmons DR. "Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays." Clin Chem. 2011;57(4):555-559. PMID: 21285256
7. Centers for Medicare & Medicaid Services. "Medicare Coverage Database: Growth Hormone." CMS.gov. Updated January 2026.
8. Aetna Clinical Policy Bulletin. "Experimental and Investigational Drugs." Policy Number 0469. Updated December 2025.
9. Internal Revenue Service. "Publication 502: Medical and Dental Expenses." IRS.gov. 2025 Tax Year.
10. Federation of State Medical Boards. "Model Policy for the Appropriate Use of Telemedicine Technologies." FSMB.org. Updated 2025.
11. ClinicalTrials.gov. "Studies of Growth Hormone Releasing Peptides." National Institutes of Health. Accessed February 2026.
12. Sigalos JT, Pastuszak AW. "The Safety and Efficacy of Growth Hormone Secretagogues." Sex Med Rev. 2018;6(1):45-53. PMID: 28784581
13. Blue Cross Blue Shield Association. "Medical Policy: Investigational Treatments." Policy 2.01.07. Updated January 2026.
14. Department of Treasury. "Health Savings Accounts: Eligible Medical Expenses." Treasury.gov. Publication 969. 2025.
15. Pharmaceutical Research and Manufacturers of America. "Biopharmaceutical Research Industry Profile 2025." PhRMA.org. March 2025.

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.